Corporate calendar for ProKidney Corp. (PROK): upcoming earnings dates, dividend ex-dates and payment dates, stock splits, shareholder meetings and conference calls. Plan your positions around the key catalysts.
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease.
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|---|---|
| 2026-09-14 | $0.03 | $1M |
| 2026-09-14 | ||
| 2026-09-14 | $0.01 | $139M |
| 2026-09-14 | ||
| 2026-09-14 | $144M | |
| 2026-09-14 | $0.06 | $3M |
Price
| Price | $1.85 |
| Market Cap | $622M |
| Exchange | NASDAQ |
| Country | US |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 1 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 8 |
| Avg rating (1-5) | 0.62 |
Related companies: BCAX · EYPT · KURA · NBTX · PRME · RZLT · SEPN
Explore sector: Healthcare · Biotechnology
More sections of PROK: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · News
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks